Pharma BD Deal Intelligence
Chugai Pharmaceutical Co. Ltd. / Araris Biotech AG
2026 · Licensing/Option · $780M · Complete
Chugai Pharmaceutical exercised its option under a Research Collaboration and Option to License Agreement with Swiss ADC company Araris Biotech, taking a license to Araris' proprietary AraLinQ linker-payload platform to generate novel antibody-drug conjugates against one target selected by Chugai. Araris is eligible for development, regulatory and commercial milestone payments plus royalties on net sales, with total potential consideration across the agreement of approximately up to US$780 million.
This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.
Key facts
- Announced Feb 10, 2026
- Deal value $780M
- Deal type Licensing/Option
- Therapeutic area Oncology
- Key assets License to Araris' AraLinQ linker-payload platform to generate novel ADCs against one Chugai-selected target
- Mechanism AraLinQ linker-payload conjugation technology for transglutaminase-mediated, site-specific antibody-drug conjugate generation
Related deals
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals
More: 2026 deals · Oncology deals